Want to see HK:0690 full AI Analyst Report?
0690 Stock Chart & Stats
HK$0.13
>-HK$0.01(-3.17%)
At close: 4:00 PM EST
HK$0.13
>-HK$0.01(-3.17%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.15
Previous CloseN/A
Volume1.74M
Average Volume (3M)4.70M
Market Cap
HK$434.87M
Enterprise ValueHK$446.27
Total Cash (Recent Filing)HK$158.87M
Total Debt (Recent Filing)HK$85.64M
Price to Earnings (P/E)8.9
Beta-0.09
Next Earnings
Mar 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.35%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding5,971,228,000
10 Day Avg. Volume1,581,333
30 Day Avg. Volume4,701,077
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)1.66
Price to Sales (P/S)1.17
P/FCF Ratio18.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Profitability And MarginsThe sustained high gross margins and solid operating and net margins show that the biologics portfolio can generate meaningful profitability after the company’s earlier turnaround. If maintained, this creates internal funding capacity for commercialization and product development while supporting resilience through normal demand fluctuations.
Manageable Leverage And Strong ReturnsModerate leverage limits balance-sheet pressure relative to the company’s equity base, while strong ROE indicates efficient use of invested capital. This combination gives Uni-Bio greater flexibility to sustain operations and pursue growth without relying excessively on additional borrowing.
Positive Recent Free Cash FlowSeveral consecutive years of positive operating and free cash flow indicate that the business has recently converted operations into cash and can support investment or shareholder returns internally. Higher free cash flow in 2025 is constructive despite the company’s broader earnings and revenue volatility.
Bears Say
Sharp 2025 Revenue ContractionThe severe 2025 revenue decline demonstrates that demand and earnings can be materially volatile despite strong margins. A prolonged contraction would weaken operating leverage, reduce the company’s capacity to fund development internally, and make recent profitability less representative of durable performance.
Uneven Cash ConversionPositive free cash flow is helpful, but consistently weaker conversion from net income raises questions about the quality and repeatability of reported earnings. This matters because sustained investment in biologics and commercialization depends on cash generation, not accounting profit alone.
Debt Has Increased In Absolute TermsThe increase in absolute debt adds a structural obligation at a time when revenue has recently weakened sharply. Although leverage remains moderate, higher borrowings could reduce financial flexibility and increase pressure on cash allocation if earnings softness persists.
Uni-Bio Science Group Ltd. News
0690 FAQ
What was Uni-Bio Science Group Ltd.’s price range in the past 12 months?
Uni-Bio Science Group Ltd. lowest stock price was HK$0.05 and its highest was HK$0.15 in the past 12 months.
What is Uni-Bio Science Group Ltd.’s market cap?
Uni-Bio Science Group Ltd.’s market cap is HK$434.87M.
When is Uni-Bio Science Group Ltd.’s upcoming earnings report date?
Uni-Bio Science Group Ltd.’s upcoming earnings report date is Mar 29, 2027 which is in 180 days.
How were Uni-Bio Science Group Ltd.’s earnings last quarter?
Uni-Bio Science Group Ltd. released its earnings results on Aug 26, 2026. The company reported HK$0.005 earnings per share for the quarter.
Is Uni-Bio Science Group Ltd. overvalued?
According to Wall Street analysts Uni-Bio Science Group Ltd.’s price is currently Overvalued.
Does Uni-Bio Science Group Ltd. pay dividends?
Uni-Bio Science Group Ltd. pays a Annually dividend of HK$0.003 which represents an annual dividend yield of 4.35%. See more information on Uni-Bio Science Group Ltd. dividends here
What is Uni-Bio Science Group Ltd.’s EPS estimate?
Uni-Bio Science Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Uni-Bio Science Group Ltd. have?
Uni-Bio Science Group Ltd. has 5,971,228,000 shares outstanding.
What happened to Uni-Bio Science Group Ltd.’s price movement after its last earnings report?
Uni-Bio Science Group Ltd. reported an EPS of HK$0.005 in its last earnings report. Following the earnings report the stock price went up 1.639%.
Which hedge fund is a major shareholder of Uni-Bio Science Group Ltd.?
Currently, no hedge funds are holding shares in HK:0690
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Uni-Bio Science Group Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.65%
12-Months-Change
Fundamentals
Return on Equity
4.35%
Trailing 12-Months
Asset Growth
8.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Uni-Bio Science Group Ltd.
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
Technical Analysis
Brii Biosciences Limited
―
Genor Biopharma Holdings Limited
―
Mabpharm Limited
―
Transcenta Holding Limited
―
Wuhan YZY Biopharma Co., Ltd. Class H
―